Clinical Trials
10 trialsNCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT04908176 2024-12-13
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
Phase 1 Completed
NCT04825574 2024-11-26
Study for Patients Previously Treated in Avapritinib Clinical Trials
Blueprint Medicines Corporation
Phase 4 Completed
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT04254939 2023-04-27
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
CStone Pharmaceuticals
Phase 1/2 Completed
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT02508532 2022-06-21
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
Phase 1 Completed
NCT03056599 2021-09-24
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
Phase 1 Completed
NCT03862885 2020-07-27
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Approved for marketing